For the first time, sales of Lyrica's generics, which is worth ₩120 billion a year, surpassed the original sales. It is the first time in nine years that a generic has been released in Korea.

The reason why it took a relatively long time to expand generic prescription performance is because the original company, Viatris, has registered material patent & use patent.

Use patent of Lyrica has been registered since the expiration of the material patent in 2012, and generic companies have sold generics in earnest since August 2017, when use patent was expired.

◆ Generics ₩16 billion vs Original ₩14.6 billion

According to UBIST, a